MUSA AKINTAYO: Open Payments
NPI 1174151344 · GREENSBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,438 in 71 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $631 · 2025 $1,438
Food & beverage: $1,438
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $327 |
| Lundbeck LLC | 13 | $223 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $219 |
| Vanda Pharmaceuticals Inc. | 6 | $180 |
| E.R. Squibb & Sons, L.L.C. | 3 | $79 |
| Teva Pharmaceuticals USA, Inc. | 5 | $78 |
| Alkermes, Inc. | 4 | $73 |
| Almatica Pharma LLC | 3 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Tris Pharma Inc | 2 | $40 |
Products named: INGREZZA, CAPLYTA, FANAPT, ABILIFY MAINTENA, REXULTI, COBENFY, ARISTADA, LOREEV XR.
Industry payments across NC — which companies pay providers there.
